
Global R&D Pipeline
My Favorite
Hot Targets:
ENPP3
Back
Total number of drugs
13
Phase II and later clinical stages
7.7%
Involving companies
14
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ-89862175 | JNJ-89862175 | Antibody drug conjugate (ADC) ADC | Neoplasms | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors | Janssen Research & Development LLC | Janssen Research & Development LLC | Phase 1 | Auristatin | JNJ-89862175 | detail > | |||||||||||
| Compound 3e(Bahauddin Zakariya University) | Compound 3e(Bahauddin Zakariya University) | Small molecule drug | Neoplasms | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors | Bahauddin Zakariya University | Bahauddin Zakariya University | Preclinical | Compound 3e(Bahauddin Zakariya University) | detail > | ||||||||||||
| ENPP3-targeted prodrug TCE(Probio) | ENPP3-targeted prodrug TCE(Probio) | Bispecific T-cell Engager (BiTE) | Neoplasms Hemic and Lymphatic Diseases | T cell surface glycoprotein CD3 stimulants Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors | Jiangsu GenScript Probio Biotech Co., Ltd. | Jiangsu GenScript Probio Biotech Co., Ltd. | Preclinical | Preclinical | ENPP3-targeted prodrug TCE(Probio) | detail > | |||||||||||
| ENPP3/CD3 Bispecific antibody(Jinsirui Vigorous) | ENPP3/CD3 Bispecific antibody(Jinsirui Vigorous) | Bispecific antibody | T cell surface glycoprotein CD3 stimulants Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors | Shanghai Jinsirui Vigorous Biotechnology Co., Ltd. | Shanghai Jinsirui Vigorous Biotechnology Co., Ltd. | Preclinical | Preclinical | ENPP3/CD3 Bispecific antibody(Jinsirui Vigorous) | detail > | ||||||||||||
| SIM0680 | SIM0680 | Antibody drug conjugate (ADC) ADC | Neoplasms | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors | Simcere Pharmaceutical Group Ltd. | Simcere Pharmaceutical Group Ltd. | Preclinical | Preclinical | SIM0680 | detail > | |||||||||||
| CN122464909 | CN122464909 | Small molecule drug | Neoplasms | Xi'an Jiaotong University | Xi'an Jiaotong University | Discovery | CN122464909 | detail > | |||||||||||||
| CN122608499 | CN122608499 | Small molecule drug | Neoplasms Other Diseases | Beijing Dr. Plant Biotechnology Co., Ltd.Dr. Plant(Guangdong)Biotechnology Co. Ltd. | Beijing Dr. Plant Biotechnology Co., Ltd. | Discovery | CN122608499 | detail > | |||||||||||||
| JP2024032952 | JP2024032952 | Recombinant polypeptide | Endocrinology and Metabolic Disease Other Diseases | Yale University | Yale University | Discovery | JP2024032952 | detail > | |||||||||||||
| WO2025240361 | WO2025240361 | Small molecule drug | Neoplasms | Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 inhibitors Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors | Board of Trustees of the Leland Stanford Junior University | Board of Trustees of the Leland Stanford Junior University | Discovery | WO2025240361 | detail > | ||||||||||||
| AGS-16M18 | AGS-16M18 | Monoclonal antibody | Neoplasms Urogenital Diseases | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors | Astellas Pharma, Inc. | Phase 1 | AGS-16M18 | detail > |
Total 13 data
1
2


